Click Therapeutics™
@Click_Tx
Followers
757
Following
315
Media
188
Statuses
329
Expanding the possibilities of medicine with patient-centric digital treatments. #clicktherapeutics #digitaltherapeutics #softwareenhanceddrugs
New York, NY
Joined July 2012
Smartphones are becoming treatment devices. From chronic pain to mental health, Software-Enhanced Drug™ Therapies are reshaping care. Our CEO, David Klein, joined @Medidata's “from Dreamers to Disruptors” to share how Click is advancing this future:
medidata.com
Is software becoming the new medicine? 📱💊 🎙️ Find out now in a new episode of "from Dreamers to Disruptors": https://t.co/VrA9fcl8Cu
0
1
1
The next breakthroughs in migraine care won’t be pills. In @MedCityNews, Click CMO Shaheen Lakhan discusses how digital tools like Click's CT-132 – a PTD for the preventive treatment of episodic migraine – are transforming treatment. Read more:
medcitynews.com
In the current phase of evolution, next-generation digital services and treatments that allow better understanding of migraine triggers, the freedom of on-demand preventative action, and pain relief...
1
0
1
In partnership with @Boehringer Ingelheim, Click Therapeutics is proud to share that CT-155 has met the primary endpoint in the CONVOKE Study, marking a positive step forward for patients suffering from negative symptoms of schizophrenia. Learn more:
clicktherapeutics.com
Click Therapeutics is redefining modern medicine with patient-centric digital treatments. Operating at the intersection of biology and technology, Click combines neuroscience with the power of...
0
2
3
ICYMI: Click Therapeutics leadership sat down with @Medidata on July 24 for an in-depth discussion on what the next frontier of patient care looks like. One key takeaway: Personalization through digitization is key. Missed the conversation? Watch here: https://t.co/qRqRAA5iH8
0
1
2
We’re heading to #BIO2025! Join Click at Booth 3678 where our team will be on-site and available for meetings to explore strategic partnerships across PDTs and Software-Enhanced Drug™ therapies. Looking to connect? Contact bd@clicktherapeutics.com
0
0
1
Click will be at #ASCO25, where our CMO Shaheen Lakhan, MD, PhD, FAAN will present our innovative oncology research. Visit us at Booth #13093, and reach out to bd@clicktherapeutics.com to request a meeting. Learn more: https://t.co/6bE2PWTlBt
@ASCO
0
0
1
CT-132, Click’s prescription digital therapeutic for migraine prevention, was featured in @neurology_live with insights from Eric Baron, DO of Cleveland Clinic. He shares how this FDA-authorized, app-based treatment can complement existing therapies:
neurologylive.com
Baron, a neurologist and headache specialist at Cleveland Clinic, explained the significance, clinical data, and patient potential behind CT-132, the first FDA-approved digital therapeutic for...
0
1
1
We’re proud to share that our Founder and CEO, David Klein, is a finalist for @EY_US Entrepreneur Of The Year New York! This honor recognizes David’s commitment to innovation and his impact on the future of patient care. Congrats to all the finalists! https://t.co/bla7Locc3n
0
0
0
Click will present Phase 3 data from the ReMMiD-C bridging study of CT-132 at the @ahsheadache 2025 Annual Scientific Meeting on Saturday, June 21 at 9:10 AM CST. Cassandra Snipes, PhD, will present abstract IOR-05. Learn more: https://t.co/bbKrbyW9xr
#AHSAM
0
0
0
CT-132, the first prescription digital therapeutic for the preventive treatment of episodic migraine in patients 18 years of age and older, has received FDA marketing authorization. Learn more: https://t.co/J3UGEIZzrg
0
0
3
Click was honored to present a poster at the AAN annual meeting on the effectiveness and safety of our first-in-class investigational PDT for the preventive treatment of episodic migraine. Read more at: https://t.co/EbpyMVdDyA
#AANAM #AAN2025
0
0
1
Click Therapeutics Founder & CEO, David Benshoof Klein, delivered a keynote address at Medidata NEXT in London last week, where Click announced closing its Series C investment round, provided entirely by @Dassault3DS . Read more here: https://t.co/wYPkFvZMvD
0
1
1
BREAKING NEWS: @Dassault3DS and Medidata have made a strategic investment in @Click_Tx. 25 years ago we revolutionized clinical trials. Today, we’re expanding the boundaries of healthcare by combining cutting-edge science with the power of software to develop new, cutting-edge
0
2
4
Today, @Dassault3DS @Medidata announced a strategic investment in Click, having provided the entire Series C funding round. The collaboration will provide a clear path to best-in-class PDTs and Software-Enhanced Drugs™ product approvals. Learn more: https://t.co/EhL1lR6sCb
0
1
2
Click Therapeutics Founder and Chief Executive Officer David Benshoof Klein shared his predictions for the pharma industry in 2025 in Healthcare IT Today. To learn more on David's insights for the new year, read the full article at:
healthcareittoday.com
As we wrap up another year and get ready for 2025 to begin, it is once again time for everyone's favorite annual tradition of Health IT Predictions! We reached
0
0
2
In his latest article for @medcitynews , our CMO Shaheen Lakhan explores how smartphones and social media contribute to a growing mental health crisis - and how the same technology that poses risks can also offer transformative health benefits. Learn more:
medcitynews.com
Addressing difficult-to-treat diseases and disorders, quickly, safely, and with little to no side effects is a positive boon to our overburdened health system.
0
0
2
Click is headed to Berlin for the @FrontiersHealth Congress taking place October 17-18. Our CEO & Founder, David Benshoof Klein, will take the stage to share his insights on the future of medicine in a keynote and fireside chat. Learn more: https://t.co/C2DxCWDTCQ
0
1
2
Click is honored to share that our CEO David Benshoof Klein has been named to the 2024 @PharmaVoice 100 list, recognizing him as a top leader in the life-sciences industry within Tech and AI. Check out the full list of inspiring leaders: https://t.co/182oNzWJpg
#PharmaVoice100
0
0
1